Asa Jellvert

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Prostate cancer (PC) was previously believed to be a chemoresistant disease. In recent years taxane-based chemotherapy has been shown to prolong survival in patients with castration-resistant prostate cancer (CRPC). It remains to be shown, however, which type of chemotherapy provides the most beneficial effect with the least amount of side effects.(More)
  • 1